Alliance Pharma plc (APH) - Net Assets
Based on the latest financial reports, Alliance Pharma plc (APH) has net assets worth GBX207.64 Million GBX (≈ $25.26K USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX369.14 Million ≈ $44.91K USD) and total liabilities (GBX161.50 Million ≈ $19.65K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check APH asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX207.64 Million |
| % of Total Assets | 56.25% |
| Annual Growth Rate | 33.71% |
| 5-Year Change | -26.09% |
| 10-Year Change | 27.83% |
| Growth Volatility | 94.28 |
Alliance Pharma plc - Net Assets Trend (1999–2024)
This chart illustrates how Alliance Pharma plc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Alliance Pharma plc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Alliance Pharma plc (1999–2024)
The table below shows the annual net assets of Alliance Pharma plc from 1999 to 2024. For live valuation and market cap data, see Alliance Pharma plc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX207.64 Million ≈ $25.26K |
-4.69% |
| 2023-12-31 | GBX217.87 Million ≈ $26.51K |
-24.26% |
| 2022-12-31 | GBX287.66 Million ≈ $35.00K |
+1.83% |
| 2021-12-31 | GBX282.49 Million ≈ $34.37K |
+0.54% |
| 2020-12-31 | GBX280.96 Million ≈ $34.18K |
+2.47% |
| 2019-12-31 | GBX274.18 Million ≈ $33.36K |
+8.72% |
| 2018-12-31 | GBX252.20 Million ≈ $30.69K |
+24.01% |
| 2017-12-31 | GBX203.38 Million ≈ $24.75K |
+13.45% |
| 2016-12-31 | GBX179.26 Million ≈ $21.81K |
+10.36% |
| 2015-12-31 | GBX162.44 Million ≈ $19.76K |
+129.50% |
| 2014-12-31 | GBX70.78 Million ≈ $8.61K |
+9.45% |
| 2013-12-31 | GBX64.67 Million ≈ $7.87K |
+24.73% |
| 2012-12-31 | GBX51.85 Million ≈ $6.31K |
+17.49% |
| 2011-12-31 | GBX44.13 Million ≈ $5.37K |
+22.30% |
| 2010-12-31 | GBX36.08 Million ≈ $4.39K |
+116.96% |
| 2009-12-31 | GBX16.63 Million ≈ $2.02K |
+89.73% |
| 2008-12-31 | GBX8.77 Million ≈ $1.07K |
+31.49% |
| 2007-12-31 | GBX6.67 Million ≈ $811.06 |
-36.10% |
| 2006-12-31 | GBX10.43 Million ≈ $1.27K |
+39.02% |
| 2005-12-31 | GBX7.50 Million ≈ $913.02 |
+9.95% |
| 2005-02-28 | GBX6.83 Million ≈ $830.41 |
+206.74% |
| 2004-02-29 | GBX2.23 Million ≈ $270.72 |
+1246.91% |
| 2003-02-28 | GBX-194.00K ≈ $-23.60 |
-108.67% |
| 2002-12-31 | GBX2.24 Million ≈ $272.16 |
+315.78% |
| 2002-02-28 | GBX538.00K ≈ $65.46 |
-9.58% |
| 2001-02-28 | GBX595.00K ≈ $72.39 |
+31.93% |
| 2000-02-29 | GBX451.00K ≈ $54.87 |
+295.61% |
| 1999-02-28 | GBX114.00K ≈ $13.87 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Alliance Pharma plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 34620.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX32.64 Million | 15.72% |
| Common Stock | GBX5.41 Million | 2.60% |
| Other Components | GBX169.60 Million | 81.68% |
| Total Equity | GBX207.64 Million | 100.00% |
Alliance Pharma plc Competitors by Market Cap
The table below lists competitors of Alliance Pharma plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Horus AG
STU:HRU
|
$4.26 Million |
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
$4.26 Million |
|
Vault Strategic Mining Corp.
V:KNOX
|
$4.27 Million |
|
NEX Metals Exploration Ltd
AU:NME
|
$4.27 Million |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
$4.25 Million |
|
Yunnan Water Investment Co. Limited
F:2WI
|
$4.25 Million |
|
Altur Slatina
RO:ALT
|
$4.25 Million |
|
PREMIER AFRICAN MINERALS
F:0PA
|
$4.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alliance Pharma plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 217,873,000 to 207,644,000, a change of -10,229,000 (-4.7%).
- Net loss of 10,729,000 reduced equity.
- New share issuances of 21,000 increased equity.
- Other comprehensive income decreased equity by 17,747,999.
- Other factors increased equity by 18,226,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-10.73 Million | -5.17% |
| Share Issuances | GBX21.00K | +0.01% |
| Other Comprehensive Income | GBX-17.75 Million | -8.55% |
| Other Changes | GBX18.23 Million | +8.78% |
| Total Change | GBX- | -4.69% |
Book Value vs Market Value Analysis
This analysis compares Alliance Pharma plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 168.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 153.24x to 168.41x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-02-28 | GBX0.42 | GBX64.70 | x |
| 2000-02-29 | GBX1.67 | GBX64.70 | x |
| 2001-02-28 | GBX0.02 | GBX64.70 | x |
| 2002-02-28 | GBX0.02 | GBX64.70 | x |
| 2002-12-31 | GBX0.15 | GBX64.70 | x |
| 2004-02-29 | GBX0.03 | GBX64.70 | x |
| 2005-02-28 | GBX0.05 | GBX64.70 | x |
| 2005-12-31 | GBX0.05 | GBX64.70 | x |
| 2006-12-31 | GBX0.07 | GBX64.70 | x |
| 2007-12-31 | GBX0.04 | GBX64.70 | x |
| 2008-12-31 | GBX0.04 | GBX64.70 | x |
| 2009-12-31 | GBX0.08 | GBX64.70 | x |
| 2010-12-31 | GBX0.14 | GBX64.70 | x |
| 2011-12-31 | GBX0.17 | GBX64.70 | x |
| 2012-12-31 | GBX0.20 | GBX64.70 | x |
| 2013-12-31 | GBX0.24 | GBX64.70 | x |
| 2014-12-31 | GBX0.27 | GBX64.70 | x |
| 2015-12-31 | GBX0.58 | GBX64.70 | x |
| 2016-12-31 | GBX0.38 | GBX64.70 | x |
| 2017-12-31 | GBX0.42 | GBX64.70 | x |
| 2018-12-31 | GBX0.49 | GBX64.70 | x |
| 2019-12-31 | GBX0.52 | GBX64.70 | x |
| 2020-12-31 | GBX0.52 | GBX64.70 | x |
| 2021-12-31 | GBX0.52 | GBX64.70 | x |
| 2022-12-31 | GBX0.53 | GBX64.70 | x |
| 2023-12-31 | GBX0.40 | GBX64.70 | x |
| 2024-12-31 | GBX0.38 | GBX64.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alliance Pharma plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.00%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.78x
- Recent ROE (-5.17%) is below the historical average (6.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 82.46% | 2.50% | 0.57x | 57.61x | GBX82.60K |
| 2000 | 34.59% | 2.49% | 1.44x | 9.65x | GBX110.90K |
| 2001 | 21.18% | 2.06% | 1.53x | 6.70x | GBX66.50K |
| 2002 | -10.41% | -0.88% | 0.72x | 16.40x | GBX-109.80K |
| 2002 | -3.15% | 0.00% | 0.00x | 1.01x | GBX-294.21K |
| 2004 | -87.87% | -18.77% | 0.39x | 11.88x | GBX-2.18 Million |
| 2005 | 5.96% | 3.44% | 0.34x | 5.03x | GBX-275.50K |
| 2005 | 8.81% | 5.38% | 0.34x | 4.77x | GBX-89.40K |
| 2006 | 4.82% | 2.92% | 0.36x | 4.61x | GBX-540.20K |
| 2007 | -48.15% | -17.61% | 0.39x | 6.96x | GBX-3.88 Million |
| 2008 | 28.65% | 11.54% | 0.45x | 5.57x | GBX1.63 Million |
| 2009 | 24.70% | 13.15% | 0.55x | 3.42x | GBX2.44 Million |
| 2010 | 24.82% | 17.95% | 0.64x | 2.15x | GBX5.35 Million |
| 2011 | 19.57% | 18.79% | 0.56x | 1.86x | GBX4.22 Million |
| 2012 | 16.76% | 19.36% | 0.45x | 1.94x | GBX3.51 Million |
| 2013 | 14.82% | 21.06% | 0.43x | 1.65x | GBX3.12 Million |
| 2014 | 11.85% | 19.26% | 0.40x | 1.52x | GBX1.31 Million |
| 2015 | 7.81% | 26.25% | 0.17x | 1.80x | GBX-3.55 Million |
| 2016 | 10.09% | 18.56% | 0.30x | 1.79x | GBX165.70K |
| 2017 | 14.21% | 27.98% | 0.31x | 1.65x | GBX8.57 Million |
| 2018 | 7.28% | 15.53% | 0.29x | 1.60x | GBX-6.86 Million |
| 2019 | 9.12% | 18.44% | 0.33x | 1.49x | GBX-2.41 Million |
| 2020 | 2.86% | 6.18% | 0.26x | 1.81x | GBX-20.07 Million |
| 2021 | 2.59% | 4.48% | 0.32x | 1.78x | GBX-20.93 Million |
| 2022 | -7.37% | -12.67% | 0.31x | 1.87x | GBX-49.97 Million |
| 2023 | -15.21% | -18.34% | 0.44x | 1.90x | GBX-54.92 Million |
| 2024 | -5.17% | -6.00% | 0.48x | 1.78x | GBX-31.49 Million |
Industry Comparison
This section compares Alliance Pharma plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,857,399,865
- Average return on equity (ROE) among peers: -65.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alliance Pharma plc (APH) | GBX207.64 Million | 82.46% | 0.78x | $4.26 Million |
| Allergy Therapeutics (AGY) | $48.53 Million | 5.95% | 0.81x | $7.66 Million |
| Animalcare Group Plc (ANCR) | $78.80 Million | -0.10% | 0.40x | $2.79 Million |
| Celadon Pharmaceuticals PLC (CEL) | $3.18 Million | -224.46% | 1.90x | $112.25K |
| Chill Brands Group PLC (CHLL) | $2.11 Million | -387.19% | 0.58x | $25.45K |
| Eco Animal Health Group Plc (EAH) | $5.52 Million | 11.11% | 0.20x | $763.17K |
| HUTCHMED China Ltd (HCM) | $84.43 Million | -21.03% | 0.40x | $20.39 Million |
| Hikma Pharmaceuticals PLC (HIK) | $48.03 Million | 21.86% | 0.98x | $37.94 Million |
| Haleon PLC (HLN) | $16.46 Billion | 6.44% | 1.12x | $372.86 Million |
| Indivior PLC (INDV) | $-11.00 Million | 0.00% | 0.00x | $18.79 Million |
About Alliance Pharma plc
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated i… Read more